Omri is an ideation facilitator, an entheogenic entrepreneur, a psychedelic musician and a psychonaut. He is passionate about the phenomenology of psychedelic experiences and the convergence of spirituality with technology. Omri leads Cybe Micromagics, which aims to increase global access by means of distributed biosynthesis. His previous company deals with nutritional solutions against cannabis overuse. Omri studied at the Berlin School of Mind & Brain and is a graduate of 8200 and TAU Lautman excellence program.
Myles has spent his career across three different continents helping to launch and lead five VC-funded startups with technological, socially responsible, and/or green focuses. During this time, he’s developed a specialty in early-stage strategy and capital raising for pioneering business models. As Co-founder and the Director of Business Development at Synthesis, Myles has been instrumental in developing infrastructure and financing for one of the world’s first legal psychedelic experience service models. In doing so, Myles is at the forefront of a worldwide movement to transform the way people approach emotional, cognitive, and spiritual well-being through safe and legal psilocybin experiences.
Mendel’s 7 years as a PhD and postdoctoral neuroscientist at Imperial College London initiated the first research on the brain mechanisms of music and psychedelics, and the role of music in psychedelic therapy. This resulted in the publication of the first evidence demonstrating music’s central role in psychedelic therapies, started the development of methods for the use of music to enhance therapy outcomes, and the vision for Wavepaths. Mendel is now considered a thought leader on the therapeutic use of music, and publishes and speaks frequently on this topic. Mendel lives and works in London (UK).
For most of his life, Gary has been a psychonautic explorer of advanced neural models, theoretical physics and manifold theory. His research led him to the conclusion that “human bodies are fruiting bodies of hyper-dimensional mycelium.” He is the patent holder of advanced 3D supercomputer architectures with extensive experience in AI and mechatronic systems design. At the turn of the millennium, Gary was developing biologic intuition synthesis algorithms in conjunction with DARPA's Polymorphic Computing Architecture project. Gary is currently focusing all of his scientific and technological expertise on his lifelong passion to revolutionize myco-cultivation infrastructure, enabling access for all, to food and medicine for body mind and spirit.
Shlomi is the chairman and founder of Eleusis. Since founding Eleusis in 2013, Shlomi has overseen the company’s corporate and clinical development efforts. Prior to founding Eleusis, Shlomi was a Managing Director at Goldman Sachs, and began his corporate career at JPMorgan.Shlomi holds an MA from New York University and a BS from Georgetown University.
Ronan Levy is the founder of Field Trip Ventures, a psychedelic therapy clinic with several locations in Canada and the US. In 2018, he cofounded Grassfed Ventures Inc., a venture capital and advisory firm focused on the cannabis, life sciences, and eSports industries.
JR is a former Silicon Valley tech executive who realized that transformational solutions to mental illness and addiction might lie in psychedelic medicines. He spent 2 years researching and began personally investing in psychedelic research through his investment company. JR partnered with drug development veteran Stephen Hurst to start Mindmed in 2019, assembling a leading clinical drug discovery and development team with vast experience conducting clinical trials and research on drug candidates derived from psychedelics. Before starting Mindmed, JR worked in market expansion and operations at Uber. After leaving Uber, he was backed by the Silicon Valley tech accelerator Y Combinator for his company Upgraded. Upgraded is partnered with Apple to provide device financing for Apple customers in Europe.
Tyler Bryden is a passionate psychedelics advocate and speaker that works in technology, marketing, and mental health. He started his entrepreneurship journey after several profound personal healing experiences with plant medicine. Tyler and the team at Sessions.ai extract meaningful insights from personal journals and recorded sessions to help improve psychedelic research, therapy, and knowledge mobilization. Tyler personally supports MAPS Canada and other organizations in the space. He also started the Forest City Psychedelic Community in London, Ontario to bring together people to inform, inspire and heal.
Lewis Goldberg is a managing partner at KCSA Strategic Communications. For more than 20 years Lewis has been working with public and private companies to leverage strategic communications to achieve specific business objectives, be they fair valuations for public equities, to help them raise capital if they are private, to define issues and move audiences or to change public policy. He has been working in the cannabis and psychedelics space for more than 6 years and has been integral in shaping new markets for nearly 2 decades. Lewis is also the co-host of the Green Rush Podcast a weekly interview show that sits at the intersection of cannabis, the capital markets and culture - with a big dash of bad dad jokes.
Dr. Sporn is a Board Certified Psychiatrist educated and trained at Duke, Univ of Miami, Tufts, The Boston Psychoanalytic Institute, and Harvard University. After practicing psychiatry in Boston and doing research at Mass General Hospital, Dr. Sporn worked at the National Institutes of Health (NIMH) where he was Chief of the OCD Clinic and helped to start up the Mood and Anxiety Program, which progressed research on ketamine and glutamate in depression. Dr. Sporn left the NIMH for Johnson and Johnson where he worked on drug development in psychiatry and neurology. He then moved to Pfizer where he worked on the development of Lyrica and was the Clinical Disease Area Expert in Neuroscience focused on Psychiatry and Addictions and the Neuroscience External R&D (business development) Leader before exiting Pfizer to Found the Biotech company, Perception Neuroscience, which is developing arketamine in neuropsychiatry. Dr. Sporn Exited Perception Neuroscience to ATAI Life Science and was the Chief Science Officer. He has subsequently left Perception Neuroscience to Co-Found another Biotech company, Gilgamesh Pharmaceuticals, that is a collaboration with Columbia University developing novel psychedelic- inspired therapies as the next generation of therapies. Gilgamesh Pharma includes many medicinal chemists as well as experienced drug developers.
Timothy Ko has a broad background of leading private ventures in the Service Sector, Investor Relations, Retail and Technology. Most recently, he served as Director of Hyperbridge Technology, a company focused on the development of decentralized technologies that facilitate crowdfunding processes.Timothy’s passion for the psychedelic space is shaped by firsthand knowledge of the shortcomings of the current mental health system, and through his exposure to psychedelics which he credits with saving his life. Following the loss of a loved one to a decades’ long fight with mental health and addictions, and through his personal experiences, Timothy has become fully committed to the life saving potential of psychedelic medicines
David is the CEO of Maya, a psychedelic therapy intelligence platform designed to bring greater trust, transparency, and measurement to the participant journey. The platform is geared to become the world's largest database of psychedelic health outcomes, fueling insights to help psychedelic healthcare scale safely. David also directs Unlimited Sciences, a psychedelic research nonprofit combining academia with data science to understand underground psychedelic practices and surface best practices to inform further research. In 2019, he served as a campaign-lead in the Denver Psilocybin Initiative, helping Denver become the first US city to reform psilocybin policy. Prior, David was Co-founder & CPO at Baker Technologies, which he exited after achieving a valuation of $250MM.
A seasoned technology executive with strong expertise in corporate finance, public markets and M&A. Most recently, Mr. Lanthier was a co-founder and CEO of Future Fertility, an innovative early stage developer of AI applications for human infertility. As a C-Suite executive, Mr. Lanthier has assisted in the growth and successful exit of numerous technology-enabled businesses through the public markets, including Mood Media, the world’s largest in-store media provider, and Fun Technologies, a pioneer in online casual games.
Ms. Blumstock brings over 25 years of experience in the life science sector, spanning from early to late stage investments. She is currently Executive Director, Corporate Development at TIAP, an early stage academic incubator in Toronto. In prior roles, Judith was a principal with Genesys Capital Partners, one of the largest Canadian venture firms focused on the life sciences industry. She was was a partner with Royal Bank Capital Partners Life Sciences Fund and Director of Bio/pharmaceutical Research at Drug Royalty Corporation (now DRI Capital). Judith received an MBA in finance from Columbia Business School and BSc in Biology from the University of Toronto.
Marik is an entrepreneur, engineer, and advocate who has worked across “counter culture” industries. He founded Iliac which built technology for performer rights in the adult entertainment industry. Later he began working with decentralized governance organizations in the blockchain space. His work focuses on providing more opportunities, resources, infrastructure, and human rights access to communities affected by cultural stigmatization.Marik is a co-founder of Tabula Rasa Ventures - a community-led investment firm focused on financing and supporting a more equitable, diverse, and compassionate psychedelic ecosystem.